The Future of GLP-1s: Why Dermatologists Should Lead the Charge in Systemic Health

“I think that GLP-1s have such a wide-reaching potential to improve health that I think that it’s something all dermatologists should sort of pay attention to,” Daniel Walker, MD, FAAD, said. “There's an opportunity for dermatologists to really learn about these medications and really grasp their potential, as much as any other specialty.”

To close out this conversation, Walker discussed the expanding therapeutic potential of GLP-1 receptor agonists, emphasizing their emerging relevance not only in dermatology but across multiple medical disciplines. While these agents are currently indicated for diabetes and weight management, growing evidence suggests broader anti-inflammatory and systemic benefits that may influence a range of disease states, in dermatologic practice and beyond.

Walker highlighted several areas of active and future investigation. Within dermatology, early observations suggest that GLP-1 receptor agonists may improve wound healing, although their role as a primary therapeutic modality in this setting remains to be defined. Additionally, ongoing and anticipated studies in psoriatic arthritis build upon prior findings in psoriasis, further supporting the hypothesis that these agents modulate key inflammatory pathways. He notes that continued research could expand into other common inflammatory dermatoses, such as atopic dermatitis and seborrheic dermatitis.

Beyond dermatology, GLP-1 receptor agonists are demonstrating promising effects in conditions such as atherosclerosis and coronary artery disease, as well as neuroinflammatory disorders, including Alzheimer’s disease and Parkinson’s disease. As new formulations—including oral agents—are developed, accessibility is expected to increase, potentially broadening patient uptake despite ongoing challenges with insurance coverage.

Walker emphasized that, despite growing enthusiasm, robust, controlled clinical trials in dermatology remain limited, and further evidence is needed to clearly define efficacy, safety, and appropriate clinical use in skin disease. Nevertheless, he encourages dermatologists to remain engaged with these developments, noting that no single specialty has yet “claimed” GLP-1 receptor agonists, thereby creating an opportunity for dermatology to play a more active role.

By addressing comorbidities such as obesity, hypertension, and insulin resistance, dermatologists may improve both cutaneous and overall health outcomes. Walker concluded that incorporating GLP-1 receptor agonists into patient discussions—particularly in those with metabolic disease—can strengthen patient engagement and support a more holistic, multidisciplinary approach to care.

“In general, we are in the business of trying to help people look better. Patients already have an established relationship of trust with us,” Walker said. “So I think that dermatologists can really play an important role in helping people's health improve, just in general.“